SYDNEY: A potential new treatment for heart attacks and strokes, developed from the venom of one of the world’s most dangerous spiders, has entered its first human clinical trial in Australia.
According to a statement from the University of Queensland, the first phase of this research will examine the safety, tolerability and dosage of IB409, a drug developed by biotech company Infensa Bioscience from a molecule found in Australian funnel-web spider venom.
The trial marks a major milestone for research that began more than a decade ago at the university’s Institute for Molecular Bioscience.
